Last reviewed · How we verify
Moxifloxacin infusion
At a glance
| Generic name | Moxifloxacin infusion |
|---|---|
| Sponsor | UCB Pharma |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- Ampicillin and Ceftriaxone for the Treatment of Enterococcus Faecalis Infective Endocarditis. (PHASE4)
- Study to Evaluate the Efficacy and Safety of Intravenous Infusion With Nemonoxacin Malate Sodium Chloride (PHASE2)
- Effect of Hyperglycaemia and Moxifloxacin on QTc Interval in T2DM (NA)
- A Study to Evaluate the Effect of Carbetocin on the QT/QTc Interval in Healthy Subjects (PHASE1)
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- A Study to Assess the Cardiac Safety of Oritavancin in Healthy Participants (PHASE1)
- A Thorough QT/QTc Study to Evaluate the Effects of an Intravenous Infusion of Eravacycline (TP-434) on Cardiac Repolarization (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Moxifloxacin infusion CI brief — competitive landscape report
- Moxifloxacin infusion updates RSS · CI watch RSS
- UCB Pharma portfolio CI